Multiple myeloma begins quietly. Virtually every case is preceded by monoclonal gammopathy of undetermined significance — a precursor state present in roughly 5% of adults over 50 — that transitions to active disease at about 1% per year. Most patients never see it coming. Median age at diagnosis is 69, and incidence varies significantly by race, with some populations diagnosed at more than twice the rate of others, often at earlier onset and with more severe presentation. The disease is largely incurable, but the window between smoldering progression and end-organ damage is where systematic monitoring matters most.
AAVBC's Multiple Myeloma Quick Reference Guide provides primary care clinicians with a structured reference for the full MM continuum — from MGUS surveillance through active disease management and remission documentation. It covers SLiM-CRAB criteria, status-specific ICD-10 coding, CRAB manifestation documentation, IMWG response category coding, and MEAT documentation standards — grounded in current NCCN and IMWG guideline evidence, and built for the clinician managing long-term follow-up in partnership with oncology.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of multiple myeloma — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
Multiple myeloma begins quietly. Virtually every case is preceded by monoclonal gammopathy of undetermined significance — a precursor state present in roughly 5% of adults over 50 — that transitions to active disease at about 1% per year. Most patients never see it coming. Median age at diagnosis is 69, and incidence varies significantly by race, with some populations diagnosed at more than twice the rate of others, often at earlier onset and with more severe presentation. The disease is largely incurable, but the window between smoldering progression and end-organ damage is where systematic monitoring matters most.
AAVBC's Multiple Myeloma Quick Reference Guide provides primary care clinicians with a structured reference for the full MM continuum — from MGUS surveillance through active disease management and remission documentation. It covers SLiM-CRAB criteria, status-specific ICD-10 coding, CRAB manifestation documentation, IMWG response category coding, and MEAT documentation standards — grounded in current NCCN and IMWG guideline evidence, and built for the clinician managing long-term follow-up in partnership with oncology.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of multiple myeloma — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
